Spectrodensitometric and ultra-performance liquid chromatographic quantification of dapagliflozin and saxagliptin in their dosage form and human plasma

Sherif A Abdel-Gawad1,2*, Obaid Afzal1
1Pharmaceutical Chemistry Department, College of Pharmacy, Prince Sattam bin Abdulaziz University, Al-Kharj 11942, Saudi Arabia, 2Analytical Chemistry Department, Faculty of Pharmacy, Cairo University, Cairo, ET-11562, Egypt
*For correspondence: Email: sagawad@yahoo.com

Abstract

Purpose: To simultaneously quantify dapagliflozin (DAPA) and saxagliptin (SAX) in a pharmaceutical product and human plasma.

Methods: Separation and quantification of DAPA and SAX were performed on pre-coated TLC plates in TLC-densitometric method using a solvent system of chloroform, ethyl acetate and methanol at a volume ratio of 8:1:1 as the mobile phase. The developed spots were scanned at 225 and 210 nm in absorbance mode. Moreover, the studied drugs were concurrently determined in human plasma using ultra-performance liquid chromatography (UPLC). The separation process was carried out in Waters™ Acquity C18 BEH column using a solvent system of 0.02 M KH2PO4 buffer, pH 4; MeOH and acetonitrile (2:1:1, v:v:v) isocratically at a flow speed of 0.5 mL/min. The absorbance of each eluent was read at 220 nm.

Results: Concurrent evaluation of DAPA and SAX was carried without separation using TLC-densitometric method, and it was successful in determination of DAPA and SAX in concentration ranges of 10 – 70 µg/band and 5 – 60 µg/band, respectively. In addition, retardation factor (Rf) values for SAX and DAPA were 0.17 and 0.31, respectively. Furthermore, the studied drugs were concurrently determined in human plasma using UPLC, which was sensitive enough to quantify DAPA and SAX in concentration ranges of 100 – 1000 and 20 – 200 ng/mL, respectively.

Conclusion: These methods can be utilized for sensitive monitoring of DAPA and SAX in pharmacokinetic and bioequivalence studies.

Keywords: TLC-densitometry, UPLC, Dapagliflozin, Saxagliptin, Simultaneous assay

INTRODUCTION

Dapagliflozin (DAPA) (1S)-1, 5-anhydro-1-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-D-glucitol, is used for controlling blood glucose levels in patients having type 2 diabetes. It enhances the elimination of blood glucose through the urine by inhibiting the protein involved in transport mechanism of sodium-glucose co-transporter (SGLT2) [1]. Saxagliptin (SAX), or (1S,3S,5S)-2-[(2S)-2-amino-2-(3-hydroxy-1-adamantyl)acetyl]-2-azabicyclo[3.1.0]...
hexane-3-carbonitrile) is an oral hypoglycemic agent which inhibits dipeptidyl peptidase 4 (DPP-4), thereby increasing insulin secretion while decreasing glucagon release from pancreatic islet cells [2]. In recent times, two or more anti-diabetic drugs are frequently prescribed for type 2 diabetes patients, and these multi-targeted therapies are more effective in hyperglycemia control than monotherapy due to their synergistic effect on management of the disease [3].

Qtern® tablet (AstraZeneca Pharmaceuticals LP, Wilmington, UK) is a pharmaceutical co-formulation product of DAPA and SAX. It is generally prescribed for control of hyperglycemia in patients where metformin, sulphonylurea and/or DAPA or SAX fail to provide sufficient control of blood sugar [4]. Several spectrophotometric [5-7] and HPLC methods [8-12] have been reported for concurrent estimation of DAPA and SAX in their co-formulation products. However, there is only one reported HPTLC method that deals with the stability study of co-formulated DAPA and SAX [13]. This method was developed for an in-house co-formulation tablet of DAPA and SAX, rather than for the marketed product. A validated LC-MS/MS method has been reported for parallel investigation of DAPA or SAX with metformin in human plasma [14].

Human plasma contents of DAPA and SAX have also been simultaneously determined using HPLC, but the key drawback of this reported method is that its linearity range does not cover the maximum plasma concentration of either DAPA or SAX [15]. In addition, another HPLC method for quantitation of DAPA and SAX uses protein precipitation technique for the preparation of samples and drug extraction from human plasma [16]. Being a non-specific technique, this procedure results in loss of analytes due to co-precipitation of matrix proteins. Furthermore, the purification method is weak, causing low detection of analytes, poor sensitivity, and low reliability of the method [17].

In this study, TLC-densitometry was used to quantify DAPA and SAX simultaneously in marketed pharmaceutical products. This developed and validated procedure can be used in routine quality control since it is simple, economical, and accurate. To the best of our knowledge, no reports are available in the literature on any procedure for quantifying the two studied drugs using ultra-performance liquid chromatography (UPLC) coupled with UV-detector. Therefore, a simple, delicate, precise, and reproducible bioanalytical UPLC technique for the quantitation of DAPA and SAX in plasma was established in the present study. The TLC-densitometric and UPLC methods were validated as per ICH-Q2B and US-FDA guidelines, respectively.

**EXPERIMENTAL**

**Chemicals and materials**

Deionized water from Milli-Q water purification unit was utilized for the preparation of samples, as required; DAPA in form of propanediol monohydrate bulk powder (purity 99.73%; CAS # 461432-26-8) was purchased from BioVision (USA), while SAX in form of hydrochloride salt bulk powder (purity 99.54%; CAS # 709031-78-7) was bought from Cayman Chemical Company (USA). Chloroform (CHCl₃), CH₃COOC₂H₅, CH₃OH, acetonitrile and o-phosphoric acid were of HPLC quality, and were purchased from Sigma-Aldrich.

**Instrumentation**

Thin layer chromatography (TLC) scanner (Model: 3 S/N 130319) run through visionCATS program, Linomat 5 autosampler and microsyringe from CAMAG® (Muttenz, Switzerland) were utilized for TLC-densitometric study. An ACQUITY UPLC setup from Waters Corporation (Elstree, UK), furnished with 500 nL flow cell and a rhodineyne injector, as well as ACQUITY UPLC BEH C18 Column (1.7 µm, 2.1 mm × 100 mm) and UV-visible wavelength detector (Waters, 2489) were used in this study.

**Human plasma samples**

Human plasma samples were kindly supplied by King Khalid Hospital, Al-Kharj, KSA.

**Pharmaceutical product**

The pharmaceutical formulation was Qtern® tablets (NDC 0310-6770-30; AstraZeneca Pharmaceuticals LP, Wilmington, UK) containing 10 mg DAPA (12.3 mg dapagliflozin propanediol) and 5 mg SAX (5.95 mg saxagliptin HCL) per tablet.

**Preparation of stock and working standard solutions**

**TLC-densitometric method**

Standard solutions of DAPA and SAX (1 mg/mL) were made by precisely weighing 25 mg of each drug, dissolving in 5 mL of distilled water and vortexing separately, prior to making up the volume to 25 mL exactly using methanol.
UPLC method

Standard stock solutions of DAPA and SAX (100 µg/mL) were made by precisely weighing 10 mg respectively, dissolving in 5 mL of distilled water and vortex-mixing separately, and bringing up the final volume to exactly 100 mL using distilled water. A 1:10 dilution of the stock solution of DAPA in distilled water comprised the working standard. The SAX working standard solution (1 µg/mL) was made by mixing 1 mL of SAX stock solution with distilled water up to 100 mL in a volumetric flask. Calibration standard and quality control solutions were made in a biological matrix similar to that used for the samples to be analyzed. The calibration curves consisted of a blank sample (biological matrix sample only) and eight non-zero samples having the serial concentrations to be quantified. Plasma calibration standard solutions were made by spiking control human plasma with standard solutions of DAPA and SAX. Eight plasma calibration samples were made for DAPA (100, 200, 300, 400, 500, 600, 800 and 1000 ng/mL), and also for SAX (20, 40, 60, 80, 100, 140, 180 and 200 ng/mL). Samples for low quality control (LQC) of DAPA (200 ng/mL) and SAX (40 ng/mL), medium quality control (MQC) of DAPA (500 ng/mL) and SAX (100 ng/mL), and high-quality control (HQC) of DAPA (800 ng/mL) and SAX (180 ng/mL), were prepared. All calibration standard solutions were vortex-mixed for 5 min to ensure proper mixing.

Extraction procedure of plasma samples for UPLC

On the day of assay, samples to be extracted were taken out in their frozen forms and allowed to thaw for one hour at room temperature. To all tubes, HCl (40 µL, 1 M) was added and vortexed. Solid phase extraction cartridges (SPE) were positioned on the extraction manifold, and each cartridge was conditioned with 2 mL of methanol, equilibrated with 2 mL of 20 mM HCl, and washed with 2 mL of water. Plasma containing DAPA and SAX were added to the cartridges, and treated with 2 mL of 20 mM HCl, followed by 4 mL methanol. The eluents collected were evaporated to dryness at 50°C under nitrogen, mixed with the mobile phase (250 µL) and loaded in auto sampler.

Method validation

The TLC densitometric and UPLC methods were validated as per ICH-Q2B [18] and US-FDA [19] guidelines, respectively.

TLC densitometric method

Linearity

Standard solutions of DAPA and SAX (1 mg/mL) were spotted as bands, with 10 mm spacing, on precoated TLC plates (silica gel 60, F254; depth: 0.25 mm; dimension: 20 cm × 20 cm), using an autosampler and micro-syringe to achieve 10 - 70 µg/band (DAPA) and 5 - 60 µg/band (SAX), respectively. The chromatographic tank was saturated for 1 h with the mobile phase (chloroform:ethylacetate:methanol; 8:1:1), and air-dried TLC plates were developed by ascending chromatography at room temperature over a distance of 15 cm. The air-dried, developed plates were then scanned at 225 and 210 nm at a scanning speed of 20 mm/sec and slit dimension of 4.00 × 0.45 mm. A calibration curve was plotted between the areas under peaks (AUPs) and drug concentrations. The respective regression equations were also calculated for DAPA and SAX.

Determination of accuracy and precision

These were assessed by evaluating three different concentrations of DAPA (10, 30 and 50 µg/band, and SAX (5, 20 and 50 µg/band) on a day (intra-day), and during 3 successive days (inter-day) as indices of quality control of samples.

Sensitivity

This was assessed using LOD and LOQ. The latter refers to the least amount of the drug that can be quantified from the background, while LOQ is the least amount of the drug that can be perfectly and precisely quantified (ICH 2005). Two of them were determined using Equations 1 and 2, as shown below.

\[
\text{Limit of detection} = 3.3\sigma/s \quad \text{(1)}
\]

\[
\text{Limit of quantitation} = 10\sigma/s \quad \text{(2)}
\]

(σ represents lowest SD, and S represents gradient of calibration curve).

Selectivity

It was determined by comparing results obtained for the mixture of DAPA, SAX and excipients with that for blank (excipients only in methanol) [18]. The selected excipients and drug-to-excipient ratio were similar as indicated in the monograph of Qtern® tablets. Selectivity was validated by analyzing in-house prepared
mixtures comprising different concentrations of the studied drugs.

**Robustness**

Robustness was validated by assessing the impact of little alterations in the assay settings, and it was evaluated by carrying out deliberate changes in the composition of the developing system.

**UPLC method**

**Linearity**

A total of nine samples (one blank and eight non-zero samples) of DAPA and SAX, ranging in concentration from 100 to 1000 ng/mL and 20 to 200 ng/mL, respectively were used. The sample solutions included samples for low quality control (LQC), medium quality control (MQC), high quality control (HQC), lower limit of quantification (LLOQ), and upper limit of quantification (ULOQ). The separation of the analytes in samples was achieved using ACQUITY UPLC BEH C18 Column (1.7 µm, 2.1 mm × 100 mm) as stationary phase. The solvent system used consisted of a combination of potassium dihydrogen phosphate (0.02 M; adjusted to pH 4), methanol and acetonitrile at a volume ratio of 2:1:1. It was pumped at a speed of 0.5 mL per min in isocratic mode, with UV-Vis detector used at a wavelength of 220 nm. The linearity was measured using the peak area ratio of the analytes by plotting a graph of MQC (external standard method) against standard concentrations. The correlation was validated by calculating the % changes in back-calculated concentrations relative to the nominal concentrations (distribution of the residuals). Except for LLOQ, when the residuals were within 15% of calibration levels, the approval standard of the calibration model was applied. The calibration curve was analyzed using slope, intercept and correlation coefficient.

**Accuracy and precision**

These were determined for LQC, MQC, HQC, and LLOQ in 6 replicates for DAPA and SAX for intra-day, along with 3 successive days for inter-day, by means of quality control samples.

**Sensitivity**

Sensitivity is the least amount of the analyte that can be estimated with reasonable accuracy and precision. It was validated using 6 replicates of LLOQ so as to define the values of LOD and LOQ.

**Specificity**

Six plasma samples from different donors were processed as indicated under Sample preparation without the addition of the studied drugs. The final extract of each sample was spiked with standard solutions of DAPA and SAX at concentrations of 200 and 40 ng/mL, respectively. Standard solutions of the studied drugs at similar concentrations in mobile phase were prepared with the same approach. Peak area for analyte for each prepared sample was then measured, and matrix effect was calculated.

**Recovery**

Recovery of drugs after the extraction process was done for LQC, MQC, and HQC samples by measuring and matching the peak areas of extracted (spiked before extraction) and un-extracted (spiked after extraction) samples.

**Stability**

The stability study of drugs in plasma was executed by keeping replicates for 24 h at room temperature. It was also carried out for 3 freeze-thaw phases by defrosting for 2 - 3 h at room temperature, and then re-freezing for 12 - 24 h. Long term stability study of drugs in plasma was also executed after storing at -28°C for 30 days. The amount of drug in plasma after each storage was compared with the original drug concentration. Drugs in plasma were labelled stable if the concentration was within the acceptable limits of accuracy and precision.

**Application of the TLC densitometric method for analysis of Qtern® tablets**

Ten Qtern® tablets were weighed precisely and the mean weight was noted. The tablets were crushed and mixed well to obtain a fine powder. Then, powder samples corresponding to 100 mg of DAPA and 50 mg of SAX were taken in a 250 mL beaker. Methanol (20 mL) and distilled water (20 mL) were added. The content was stirred for 20 min, filtered into a volumetric flask (100 mL), and the residue was washed with methanol (2 × 10 mL). The volume of the flask content was adjusted to 100 mL by adding methanol, with extensive stirring. The amount of each drug was determined using the TLC-densitometric method. The concentrations of DAPA and SAX were determined from their respective regression equations. Furthermore, standard additions were made via addition of various amounts of bulk DAPA and SAX in the formulation, and then analyzing using the proposed analytical method.
RESULTS

Method validation

**TLC densitometric method**

The ICH-Q2B guidelines were adopted for the validation of TLC densitometric method. The separation pattern is shown in Figure 1.

**Figure 1:** TLC-densitometric separation patterns of DAPA and SAX

**Linearity**

Linearity was evaluated by plotting peak area against drug concentrations of 10-70 µg/band for DAPA, and 5 - 60 µg/band for SAX. The respective regression equations are presented in Equations 3 and 4.

\[
PADAPA = 1.762C + 198.48 \quad (r^2 = 0.9996) \quad \ldots \quad (3)
\]

\[
PASAX = 4.789C + 356.45 \quad (r^2 = 0.9997) \quad \ldots \quad (4)
\]

where PA represents area under peak, and \( r^2 \) represents correlation coefficient.

**Accuracy**

Accuracy was analyzed with quality control samples consisting of 3 concentrations each of DAPA and SAX within the stated linearity range. The accuracy of the developed procedure was confirmed by determining recovery and % RSD which were found to be satisfactory (Table 1).

**Precision**

Three concentrations each of DAPA and SAX were evaluated using the proposed TLC-densitometric method for the duration of one day (intra-day) and 3 consecutive days (inter-day). The % RSD was below 2 for both, confirming good precision of the developed procedure (Table 1).

**Sensitivity**

The sensitivity of the procedure was studied with LOD and LOQ, and their levels established that its sensitivity was acceptable.

**Robustness**

This was confirmed using minor alterations in settings of the method, which resulted in effects smaller than 1% RSD (Table 1).

**UPLC method**

The US-FDA guidelines were adopted for the validation of UPLC method.
Table 2: Application of the proposed TLC-densitometric method for the determination of DAPA and SAX in laboratory-prepared mixtures

| Parameter                              | DAPA    | SAX    |
|----------------------------------------|---------|--------|
| Claimed concentration of DAPA/SAX mixture | 10 mg   | 5 mg   |
| Mean ± SD* (n=3)%                      | 102.52 ± 0.997 | 98.99 ± 0.8320 |
| RSD                                    | 0.972   | 840    |
| Claimed concentration of DAPA/SAX mixture | 5 mg   | 5 mg   |
| Mean ± SD* (n=3) %                     | 100.86 ± 0.542 | 101.83 ± 1.211 |
| % RSD                                   | 0.537 | 1.211 |
| Claimed concentration of DAPA/SAX mixture | 10 mg | 20 mg |
| Mean ± SD* (n=3) %                     | 100.56 ± 0.682 | 98.66 ± 0.764 |
| % RSD                                   | 0.678   | 0.774  |

*Standard deviation

**Linearity**

The peak area ratio of each studied drug was used to plot the calibration curve. Linearity of the procedure was recognized by an 8-point calibration curve covering concentrations of 100 - 1000 ng/mL for DAPA, and 20 - 200 ng/mL for SAX. The respective regression equations are shown in Equations 5 and 6 for DAPA and SAX, respectively.

\[ \text{PARDAPA} = 0.002C - 0.011 \quad (r^2 = 0.9983) \]  
\[ \text{PARSAX} = 0.010C - 0.006 \quad (r^2 = 0.9988) \]  

where \( PAR \) represents peak area ratio and \( r^2 \) represents correlation coefficient. The high correlation coefficient values validated the linearity of the method.

**Accuracy and precision**

Six LLOQ, LQC, MQC, and HQC replicate samples were analyzed in the determination of accuracy and precision. The outcomes are displayed in Table 3.

**Sensitivity**

The LOD and LOQ were determined in blood samples, and it was found that 100 ng/mL of DAPA and 20 ng/mL of SAX were detected in all calibrators and consistently gave acceptable precision values when back-calculated. The signal-to-noise ratio at LLOQ was consistently more than 3. The calculated corresponding LOQs of DAPA and SAX were 100 ng/mL and 20 ng/mL, respectively.

**Specificity**

Matrix effect was determined to validate the specificity of the developed procedure. There

Table 3: Summary of accuracy and precision (inter-day and intra-day) for the proposed UPLC-method

| Parameter | DAPA          | SAX           |
|-----------|---------------|---------------|
| Day 1     |               |               |
| \( \text{LLOQ}^a \) | \%Mean ± SD* (n=6) | 102.48 ± 1.459 | 101.88 ± 1.341 |
|           | % RSD          | 1.424 | 1.316 |
| \( \text{LOQ}^b \) | \%Mean ± SD* (n=6) | 101.69 ± 1.231 | 99.18 ± 0.769 |
|           | % RSD          | 1.211 | 0.775 |
| \( \text{MQC}^c \) | \%Mean ± SD* (n=6) | 97.98 ± 1.112 | 101.54 ± 1.872 |
|           | % RSD          | 1.134 | 1.843 |
| \( \text{HQC}^d \) | \%Mean ± SD* (n=6) | 98.46 ± 0.986 | 99.12 ± 1.873 |
|           | % RSD          | 1.001 | 1.890 |
| Day 2     |               |               |
| \( \text{LLOQ}^a \) | \%Mean ± SD* (n=6) | 101.56 ± 1.119 | 102.12 ± 1.241 |
|           | % RSD          | 1.101 | 1.215 |
| \( \text{LOQ}^b \) | \%Mean ± SD* (n=6) | 98.56 ± 0.765 | 99.57 ± 1.855 |
|           | % RSD          | 0.776 | 1.863 |
| \( \text{MQC}^c \) | \%Mean ± SD* (n=6) | 101.65 ± 1.398 | 101.48 ± 1.439 |
|           | % RSD          | 1.375 | 1.418 |
| \( \text{HQC}^d \) | \%Mean ± SD* (n=6) | 103.12 ± 1.457 | 102.99 ± 1.873 |
|           | % RSD          | 1.413 | 1.819 |
| Day 3     |               |               |
| \( \text{LLOQ}^a \) | \%Mean ± SD* (n=6) | 99.39 ± 0.896 | 99.36 ± 0.876 |
|           | % RSD          | 0.901 | 0.881 |
| \( \text{LOQ}^b \) | \%Mean ± SD* (n=6) | 103.12 ± 1.652 | 102.89 ± 1.824 |
|           | % RSD          | 1.602 | 1.773 |
| \( \text{MQC}^c \) | \%Mean ± SD* (n=6) | 99.62 ± 1.254 | 100.95 ± 0.549 |
|           | % RSD          | 1.259 | 0.544 |
| \( \text{HQC}^d \) | \%Mean ± SD* (n=6) | 102.78 ± 1.113 | 102.45 ± 1.923 |
|           | % RSD          | 1.083 | 1.877 |

*Standard deviation; \(^a\)100 ng/mL DAPA and 20 ng/mL SAX; \(^b\)200 ng/mL DAPA and 40 ng/mL SAX; \(^c\)500 ng/mL DAPA and 100 ng/mL SAX; \(^d\)800 ng/mL DAPA and 180 ng/mL SAX
Table 4: Extraction recovery from plasma samples

| Concentration | DAPA | SAX |
|---------------|------|-----|
|               | % Recovery* | % RSD | % Recovery* | % RSD |
| LQC<sup>a</sup> | 89.56 | 1.312 | 84.13 | 1.191 |
| MQC<sup>b</sup> | 88.34 | 0.823 | 85.43 | 1.135 |
| HQC<sup>c</sup> | 87.81 | 0.578 | 89.23 | 0.432 |

*Average of six readings; <sup>a</sup>200 ng/mL DAPA and 40 ng/mL SAX; <sup>b</sup>500 ng/mL DAPA and 100 ng/mL SAX; <sup>c</sup>800 ng/mL DAPA and 180 ng/mL SAX

Table 5: Stability data for DAPA and SAX in human plasma

| Storage condition | DAPA | SAX |
|-------------------|------|-----|
|                   | LOQ (200 ng/mL) | MQC (500 ng/mL) | HQC (800 ng/mL) | LOQ (40 ng/mL) | MQC (100 ng/mL) | HQC (180 ng/mL) |
| Bench-top stability | 97.49 ± 0.981 | 98.94 ± 0.752 | 103.55 ± 0.965 | 98.86 ± 0.832 | 96.64 ± 0.753 | 102.46 ± 0.987 |
| Freeze-thaw stability | 103 ± 0.854 | 98.36 ± 0.915 | 104.43 ± 1.298 | 102.874 ± 0.549 | 97.13 ± 0.913 | 103.43 ± 0.913 |
| Long term stability | 97.78 ± 0.987 | 97.78 ± 0.987 | 102.99 ± 0.987 | 95.89 ± 1.876 | 98.98 ± 1.732 | 101.98 ± 1.274 |

*Standard deviation was no interference from the biological matrix on the studied drugs. The calculated average matrix effects for DAPA and SAX were 105.50 and 1094.89 %, respectively.

Recovery

The recovery of DAPA and SAX were assessed by matching the average peak areas of six LQC, MQC and HQC replicate samples with corresponding average peak areas of unextracted samples. The results were within acceptable limits, as presented in Table 4.

Stability

This was investigated by means of 6 replicates of LQC, MQC and HQC samples, over 24 h at room temperature (bench-top stability). The concentrations were then matched with those of freshly prepared and processed samples, and the results suggested the stability of DAPA and SAX in plasma when stored at room temperature for 24 h. The stability was also tested for three consecutive freeze-thaw cycles. Moreover, long term stability was evaluated for 30 days at -28°C for same quality control concentration levels. All the acquired data indicated stability of the drugs, as shown in Table 5.

Use of TLC densitometric procedure for analyzing Qteln<sup>®</sup> tablets

In order to ensure content uniformity in Qteln<sup>®</sup> tablets, DAPA and SAX were quantified using the proposed method (Table 6). The pharmaceutical products showed satisfactory recoveries, within adequate content uniformity limits. The consistency and applicability of the proposed method were certified by adding various known amounts of pure DAPA and SAX into the formulation, by standard addition method. The results showed significant recoveries of added drugs using the suggested method (Table 6).

Table 6: Determination of DAPA and SAX in Qteln<sup>®</sup> tablets and evaluation of recovery of added standard using the new UPLC procedure

| Compound | Uniformity | Added standard |
|----------|------------|----------------|
| DAPA | Mean±SD* | 102.67±1.764 | 101.11±0.763 |
| SAX | Mean±SD* | 101.11±0.549 | 99.58±0.549 |

*Standard deviation, average of three determinations

DISCUSSION

In this work, two sensitive and accurate analytical methods were adopted to simultaneously quantify DAPA and SAX in their dosage form (TLC-densitometric method) and in human plasma (UPLC-method). In the TLC-densitometric method, adequate separation of the studied drugs was done with a solvent system consisting of CHCl<sub>3</sub>, CH<sub>3</sub>COOC<sub>2</sub>H<sub>5</sub> and CH<sub>3</sub>OH at a volume ratio of 8:1:1. The retardation factor (R<sub>f</sub>) for SAX and DAPA were found to be 0.17 and 0.31, respectively. This method has advantage in that it can be used to run several samples at the same time, making it very suitable for application in the quality control laboratories. The cited method was validated according to the ICH-Q2B guidelines regarding linearity, accuracy, precision, selectivity, sensitivity and robustness.
Moreover, a UPLC method was developed and optimized for excellent separation pattern of DAPA and SAX. This was done using Waters™ ACQUITY UPLC BEH C18 Column as stationary phase, and a mixture of potassium dihydrogen phosphate buffer (0.02 M; adjusted with orthophosphoric acid to pH 4), methanol and acetonitrile at a volume ratio of 2:1:1 as mobile phase (Figure 2). The UPLC technique has the advantage of using ultra-small size of the packing material to ensure excellent resolution of the studied drugs. The proposed procedure was fully validated according to the US-FDA standards regarding accuracy, linearity, precision, sensitivity, specificity, recovery and stability. The validation scheme showed good results as demonstrated in Tables 3, 4 and 5. The method can be best used in monitoring of these drugs in pharmacokinetic and bioequivalence studies.

**DECLARATIONS**

**Conflict of interest**

No conflict of interest is associated with this work.

**Contribution of authors**

We declare that this work was done by the authors named in this article and all liabilities pertaining to claim relating to the content of this article will be borne by the authors.

**Data availability**

All the data associated with this research have been included in the manuscript.

**Open Access**

This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.

**REFERENCES**

1. Sanagapati M, Dhanalakshmi K, Reddy GN, Kavitha B. Method development and validation of dapagliflozin API by UV spectroscopy. Int J Pharm Sci Rev Res 2014; 27: 270-272.
2. Sawant RL, Mhaske SM. Analytical method development for simultaneous estimation of saxagliptin and methyldopa. Asian J Pharm Res 2014; 4: 134-140.
3. Bailey CJ, Day C. Fixed-dose single tablet antidiabetic combinations. Diabetes Obes Metab 2009; 11: 527-533.
4. Williams DM, Stephen JW. Combination therapy with saxagliptin and dapagliflozin for the treatment of type 2 diabetes. Expert Opin Pharmacother 2015; 10: 2373-2379.
5. Lotfy HM, Mohamed D, Elshahed MS. Novel univariate spectrophotometric determination of the recently released solid dosage form comprising dapagliflozin and saxagliptin via factorized response spectra: Assessment of the average content and dosage unit uniformity of tablets. Spectrochim Acta A Mol Biomol Spectrosc 2019; 222: 117120.
6. Bhadauria RS, Agarwal V. Development and Validation of UV Spectroscopic Method for Simultaneous Estimation of Dapagliflozin and Saxagliptin in marketed formulation. J Drug Deliv Ther 2019; 9(4-s): 1160-1164.
7. Suthar AM, Prajapati LM, Joshi AK, Patel JR, Kharodiya ML. Estimation of Saxagliptin hydrochloride and Dapagliflozin propendiol monohydrate in combined dosage form. J Innov Appl Pharm Sci 2018; 3(2): 01-07.

8. Deepan T, Dhanaraju MD. Stability indicating HPLC method for the simultaneous determination of dapagliflozin and saxagliptin in bulk and tablet dosage form. Curr Issues Pharm Medical Sci 2018; 31: 39-43.

9. Patel PD, Pandya SS. Validated RP-HPLC method for simultaneous estimation of dapagliflozin and saxagliptin hydrochloride in tablet dosage form. Int J Pharm Res Scholars 2018; 7: 9-15.

10. Swamy GK, Shruthi S, Rajkumar M, Kumar DS. A new stability indicating RP-HPLC method for simultaneous determination of saxagliptin and dapagliflozin in bulk and combined tablet dosage forms. Asian J Pharm Anal Med Chem 2017; 5: 113-121.

11. Singh N, Bansal P, Maithani M, Chauhan Y. Development and validation of stability-indicating RP-HPLC method for simultaneous determination of saxagliptin and dapagliflozin in fixed-dose combination. New J Chem 2018; 42: 2459-2466.

12. Usman RM, Ahmad S, Deore C, Shaikh T, Jain B, Imran M. Stability Indicating RP-HPLC Method for Determination of Saxagliptin and Dapagliflozin in Bulk and Tablet Dosage Forms. J Pharm Sci Res 2020; 12(4): 499-506.

13. Ahmed HM, Omar MA, Batakoushy HA, Hamid MAA. HPTLC-densitometric analysis of selected antidiabetic drugs in presence of their degradation products. Microchem J 2020; 154: 104560.

14. El-Zaheer AA, Hashem HA, Elkady EF, Allam MA. A validated LC-MS/MS bioanalytical method for the simultaneous determination of Dapagliflozin or saxagliptin with metformin in human plasma. Microchem J 2019; 149: 104017.

15. Kommineni V, Chowdary KPR, Prasad SVUM. Development and Validation of a New HPLC Method for the Simultaneous Estimation of Saxagliptine and Dapagliflozin and Its Application in Pharmacokinetic Studies. Int J Pharm Biomedical Res 2018; 1(6): 16-24.

16. Donepudi S, Achanta S. Simultaneous Estimation of Saxagliptin and Dapagliflozin in Human Plasma by Validated High Performance Liquid Chromatography - Ultraviolet Method. Turkish J Pharm Sci 2019; 16(2): 227-233.

17. Andersson LI. Molecular imprinting for drug bioanalysis: A review on the application of imprinted polymers to solid-phase extraction and binding assay. J Chromatogr B 2000; 739: 163-173.

18. Guideline IHT. Validation of analytical procedures: text and methodology Q2 (R1). International Conference on Harmonization, Geneva, Switzerland, 2005.

19. Food Drug Administration (FDA). Guidance for Industry: Bioanalytical Method Validation US Department of Health and Human, Services Food and Drug Administration, and Center for Drug Evaluation and Research, 2001